Since both YAP-1 and PARP-1 play critical roles in GBM progression and resistance, simultaneously inhibiting these two proteins could offer a synergistic strategy to overcome therapeutic resistance and improve clinical outcomes. The gene discussed is PARP1; the disease is glioblastoma.